

Jubilant Ingrevia Limited

Investor Presentation

October 2024



Creating Value,
Growing Sustainably



Disclaimer



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

NOTES:

1. The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary
2. Closing Exchange Rate for USD 1 a Rs 83.8 as on September 30, 2024, Rs 83.4 as on June 30, 2024 and Rs 83.4 as on March 31, 2024.

Chairmen's Message on Q2'FY25 Financial Results | 1/2



Mr. Shyam S Bhartia
Chairman
&
Mr. Hari S Bhartia
Co-Chairman

"We are pleased to announce a healthy QoQ & YoY growth for the quarter, fueled by the enhanced performance of our Speciality Chemicals and Nutrition & Health Solutions Businesses, as well as the advantages gained from cost-saving measures implemented over the last few quarters.

Markets Update:

*Globally, the **Chemical markets are gradually improving in 2024** with volumes showing a marginal growth over last year. We are witnessing the same in our businesses.*

*The **Pharmaceutical end-use segment** continues to experience steady demand, supported by stable pricing and volume placements. Our Pharma folio in Fine Chemicals business reflects the same sentiments. We continue to face pressure in the Acetyls business though, due to low demand in the Paracetamol segment.*

*The **Agrochemical sector** is beginning to show some signs of improvement. The excess inventory situation is gradually resolving and volumes are recovering in Pyridine based products. We are optimistic that this steady recovery will continue over the coming quarters.*

*In the **Nutrition Segment**, demand remained steady, with Niacinamide volumes showing an upward trend and prices rising during the quarter. Meanwhile, Choline demand remained stable, although pricing pressure continued due to high imports.*

Business Update:

*In the **Speciality Chemicals Business**, we saw a notable increase in volumes of high-margin Fine Chemicals business in both QoQ and YoY. The Pyridine & Picolines segment showed material YoY growth driven by higher volumes. The CDMO business continues to show good traction with customers across pharma, agrochemicals and semi-conductor segments (early stage).*

*In the **Nutrition and Health Solutions Business**, significant YoY and QoQ growth was driven by increased volumes and prices of Niacinamide. Margin growth was boosted by better product mix with higher share of volumes (versus last quarter) from human grade products.*

Chairmen's Message on Q2'FY25 Financial Results | 2/2



*In the **Chemical Intermediates Business**, QoQ growth was attributed to an increase in volumes of Ethyl Acetate and Acetic Anhydride. However, the YoY performance declined mainly due to lower prices.*

Agrochemical CDMO Update:

We are excited to share that we have signed a five-year agreement with a multinational Agro-innovator to produce a key intermediate for one of their strategic agrochemicals. Jubilant Ingrevia Limited will manufacture this intermediate using the MNC's proprietary technology. As a result of this contract, the company anticipates a significant increase in overall revenue share from its agrochemical CDMO business post commencement of production.

World Economic Forum- Global Lighthouse Network Update:

We are glad to announce our inclusion in the prestigious Global Lighthouse Network (GLN) of the World Economic Forum (WEF). The WEF has recognised Jubilant Ingrevia Limited's Bharuch manufacturing facility as a Global Manufacturing Lighthouse, making us the only Indian company to achieve this distinction in this cohort. Over the past few years, we have made significant investments to digitally transform our plants, and the results are evident in enhanced efficiency, environmental performance, and safety measures. We are grateful to the WEF for their ongoing partnership in this journey.

Future Outlook:

We expect to see improvements in our overall business performance in FY25, particularly within Speciality Chemicals and Nutrition & Health Solutions segments. Consistent with last few quarters, our primary focus remains on customer-centricity, utilising the newly commissioned plants, enhancing operational efficiency leading to further improvement in margins. We expect sequential improvement in performance in Q3 and Q4, with H2FY25 to be even better vs. H1FY25.

We are committed to our growth plans through our ambitious Pinnacle 345 vision of achieving three times revenue and four times EBITDA within five years."



Mr. Shyam S Bhartia

Chairman

&

Mr. Hari S Bhartia

Co-Chairman



Table of Contents

06

Company Overview

11

Growth Roadmap

15

Q2'FY25 Highlights

22

Business Segments Update



Company Overview



Our Lighthouse Site Visuals



Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group

<p>3rd largest Company in the Jubilant Group</p>	<p>45+ years of legacy in Chemicals space, started in 1978 as VAM Organic Chemicals</p>	<p>2300+ people with strong leadership team with average 25+ years of experience in Chemicals space</p>
---	--	--



Network of 5 state of art manufacturing facilities and 3 R&D centres with 131 Qualified scientists including 26 PhDs



Rs 1,045 Cr
Revenue Q2'FY25

Rs 2,070 Cr
Revenue H1'FY25



Rs 135 Cr | 12.9%
EBITDA & Margin Q2'FY25

Rs 254 Cr | 12.3%
EBITDA & Margin H1'FY25




130+
Products commercialized across business segments



1500+
Customers catered globally
Serving 15 of Top 20 Pharma and 7 of Top 10 Agrochem customers


Our business is split across 3 business verticals, with global leadership across our key product lines



Specialty Chemicals

- CDMO (Pharma, Agro, Semi-con)
- Fine Chemicals
- Bio-Pyridine and Bio-Picolines


- **Globally #1** player in Bio-Pyridine, Bio Beta.
- **Globally #1** in 18 Pyridine Derivatives.
- **Only scaled non-Chinese player.**



Nutrition & Health Solutions

- Nutrition & Health Ingredients
- Animal & Human Nutrition Health Solutions

- **Globally #2** in Vitamin B3
- **Domestic leader** in Vitamin B4



Chemical Intermediates

- Acetyls

- **Globally #2** in Acetic Anhydride Merchant Market capacity

Before adjustment of Unallocated corporate expense/Income

We serve customers across geographies and sectors; increased growth from exports and pharma/cosmetic/nutrition sectors in recent years




Our Product Platforms

Enable us to serve diverse customer segments and market needs

- 1 *Pyridine*
- 2 *Diketene*
- 3 *Acetyls*
- 4 *Pyrithiones*
- 5 *Niacinamide*
- 6 *Choline*
- 7 *Piroctone Olamine*
- 8 *Multiple CDMO molecules*




Geographical Revenue Split (Q2'FY25)



■ India ■ Europe & Japan
 ■ North America ■ ROW

End-use Industry Revenue Split (Q2'FY25)



■ Pharma ■ Agrochemical ■ Nutrition
 ■ Industrial ■ Consumer

Continuous focus on building upon platform & use cases, e.g.

- Choline: Advancing to pharma & food grade Choline Bitartrate
- Niacinamide: Higher grade Niacinamide for cosmetics and food applications

- **Increasing share of exports:** 48% in Q2FY25 vs 38% in Q2FY24 thus reducing reliance on domestic market
- **North America witnessed YoY Growth of 22%**
- **Exports grew 30% YoY** with EU & Japan leading growth

- **Significant YoY growth in Food Grade Nutrition** end-use products



Executive Leadership Team

Energized & experienced leadership team



Deepak Jain
CEO & MD
20 years of industry & Consulting experience



Chandan Singh
Advisor
37 years of industry experience

Business Leaders

Specialty Chemicals



Ambrish Dixit
Head of Specialty Chemicals
22 years of industry experience

Nutrition & Health



Ashish Kr. Sinha
Business Head- Animal & Human Nutrition
25 years of industry experience

Chemical Intermediates



Himanshu Dhapola
Business Head- Acetyls
22 years of industry experience



Yuvraj B
Business Head- CDMO
18 years of industry experience



Sumit Das
Business Head Nutrition Ingredients
31 years of industry experience



Anurag Krishan
Business Head – Fine Chemicals
19 years of industry experience



Amit Saini
Business Head – Pyridine & Picolines
21 years of industry experience

Function Leaders



Varun Gupta
Chief Financial Officer
18 years of industry experience



Vijay Kumar Srivastava
Head of Operations
24 years of industry experience



Birajeev Singh
Head of Supply Chain
23 years of industry experience



Vinita Koul
Head of HR
27 years of industry experience




Parthasarathy Basu
Head of Strategy
17 years of industry experience



Gaurav Kushwaha
Chief Digital Information Officer
24 years of industry experience

Growth Roadmap (Recap)



Our new 'Compass' forms the bedrock of our future growth roadmap



PURPOSE

Enable a Sustainable World through Chemistry



VISION

Leading provider of innovative solutions in our core chemistries globally



CAPABILITIES/ CORE PILLARS

Customer Centricity

Customer-first approach to deliver best solutions, service, quality, cost

World-class, Safe Operations

Highest quality and efficient operations, enabled by Digital/Analytics; Zero tolerance mindset towards safety

Innovation & Technology

Innovative products/ solutions by pushing 'technology boundaries'

ESG Leader

Amongst ESG leaders in India/globally

People Focused

Attract, develop and retain the best talent; Best place to work

Inspire

Agile, role model, higher ownership, empowerment

Challenge

Bold, go extra mile, increase efficiency

Innovate

Creative, curious, fail fast approach, solution mindset

Excel

Reliable, integrity, first time right, strive to excel

Collaborate

Trust, considerate, team-player



VALUES

Recap: Future Growth Aspiration to grow 3x in next 5 years



PINNACLE 3.4.5

3 times REVENUE 


4 times EBITDA 

5 year HORIZON 


Last one year: We have already started to make good progress in our Pinnacle 345 journey



Major events / milestones



Q2 & H1'FY25 Highlights



Market Overview: Q2 & H1'FY25 | Gradual recovery in volumes across segments; prices are still soft in most segments



PHARMA

- **Steady demand with good visibility on volumes** across segments; volume growth seen in Pyridine derivatives
- **Stability in prices** across segments; uptick in some areas
- **Paracetamol driven demand remained under pressure** with customers running their plants at sub-optimal capacities

AGROCHEM

- **Demand is gradually coming back**, issues relating to global inventory destocking waning out, complete recovery expected to be gradual
- **Volumes gradually recovering in Pyridine based products**
- **Additional capacity in select Agrochem products** in future years to further move Pyridine demand

NUTRITION

- Niacinamide **volume offtake increasing**; prices seeing an **upward tick**
- Stable demand in Choline, but **pricing pressure from international competition** for most of Q2
- Gradually **increasing traction** in **Human nutrition** grade products



Key business highlights Q2FY25: Significant growth in our core categories, higher margins on account of product mix & cost initiatives

Core product platforms continue to drive growth and leadership; maintained market share despite tough headwinds in Acetyls

- **Pyridine & Picoline:** Significant volume growth on YoY basis; world's largest and only non-Chinese scaled player in Pyridine
- **Niacinamide:** Maintained leadership position (Top 2) in feed grade with steady QoQ growth in volumes and marginal uptick in prices
- Acetic Anhydride: Marginal QoQ growth in volumes, prices continue to be under pressure; maintained market share in H1FY25

Steady share of Specialty & Nutrition, robust revenue growth

- **59% revenue share and 73% EBITDA share** of Specialty & Nutrition in overall portfolio
- Fine Chemicals, Microbials, and Nutrition showing **strong YoY revenue growth**
- **New product lines:** Diketene Derivatives, Semiconductors

Big-wins in Agro; high engagement with customer roadshows continues

- Secured orders in Agro space with two largest MNC Agro Innovators
- 7 Customer **Roadshows done in Japan, Europe, US and China**
- **High levels of interest** to engage and work across Agro, Pharma and Semi-con space

Unlocking efficiency, enhancing safety, continuing ESG focus

- **Strategic initiatives continue to deliver:** Substantial savings from Surge, Lean, BE and Energy
- Increased safety measures via focusing on **'5S' culture**
- **On-track** for achieving **5-year RE target**; RE agreement at Bharuch & Savli – Bharuch discussion on

Capex on track

- **Long-term capex plans in pipeline** with continued investments in new opportunities such as Food and Cosmetic grade Niacinamide (**On track for Q3FY25 commissioning**) and MPPs

Strengthened leadership team

- **New CFO (Varun Gupta, 18+ yrs at Unilever)** joined in Aug
- **New Supply Chain Head (Birajeev Singh)** joined in Sep

Global & domestic recognitions

- **Bharuch** manufacturing site designated as a **Global Lighthouse location by WEF**; **"Company of the Year"** award by FICCI

Financial Results Overview | Q2 & H1'FY25 Consolidated



Particulars ¹	Q2'FY24	Q1'FY25	Q2'FY25	Q-o-Q	Y-o-Y	H1'FY24	H1'FY25	Y-o-Y
Total Revenue	1,020	1,024	1,045	2.0%	2.5%	2,095	2,070	-1.2%
Total EBITDA	126	119	135	13.4%	7.0%	251	254	1.1%
EBITDA Margin (%)	12%	12%	13%			12%	12%	
Profit After Tax	57	49	59	21.1%	2.6%	115	108	-6.4%
Profit After Tax Margin (%)	6%	5%	6%			5%	5%	
Basic and Diluted EPS (Rs.)	3.6	3.1	3.7	21.1%	2.5%	7.3	6.8	-6.3%

Revenue & EBITDA during the quarter was impacted on account of :




Speciality Chemicals

Incremental Sales traction from **Pyridine building blocks and Fine Chemicals**.



Nutrition & Health Solutions

Healthy growth in **Vitamin B3 Volumes and prices** leading to growth in revenue.



Chemical Intermediates

QoQ growth due to uptick in volumes of **Ethyl Acetate and Acetic Anhydride**

YoY performance driven by **lower prices of Acetic Acid and lower demand**



Higher freight cost


Continued impact of increased logistics costs, resultant of container shortages and higher shipment costs due to Red Sea crisis.

1. All figures are in Rs Crore unless otherwise stated

We are seeing a gradual recovery from the lows of H2'FY24



EBITDA (INR Crs.) EBITDA Margins



Revenue (INR Crs.)


We continue to see secular YoY and QoQ EBITDA growth across Specialty Chemicals and Nutrition along with margin expansion



Specialty Chemicals

EBITDA (Rs Cr.)

Y.o.Y Growth 26%
Q.o.Q Growth 1%




- Significant Improvement in Volumes of high margin Fine Chemicals' Pyridine derivatives on QoQ & YoY basis
- Di-ketene plant operating at healthy utilization levels
- YoY margin growth in Pyridines driven by higher volumes

Nutrition & Health Solutions

EBITDA (Rs Cr.)

Y.o.Y Growth 29%
Q.o.Q Growth 5%



- Increase in volumes and prices of Niacinamide led the margin growth
- Shift in volumes mix towards human grade product led improvement in EBITDA on QoQ and YoY basis

% EBITDA Margins – Before adjustment of Unallocated corporate expense/Income

WEF recognises Bharuch facility as a Global Manufacturing Lighthouse



Jubilant Ingrevia is now a member of the elite Global Lighthouse Network (GLN) of the World Economic Forum (WEF)



Global Lighthouse Network

GLN is a community of 172 industry leaders pioneering the use of cutting-edge Fourth Industrial Revolution (4IR) technologies in manufacturing. Less than 2% companies are awarded after a 6-month long evaluation process by global experts.

Bharuch manufacturing site is designated as WEF Lighthouse location

- *First chemical manufacturing plant in Asia*
- *First manufacturing plant from India in 2024*
- *Only Indian company in same cohort*

Jubilant Ingrevia deployed 4IR technologies in global brownfield speciality chemical manufacturing and reskilling its employees, making them 'digital ready'. Over the coming years, the company intends to institutionalise digital interventions across all its plants

Digital Impact @ Bharuch

- **Efficiency:** Reducing production losses by >30% and increasing workforce productivity by >20%
- **Environment:** >20% reduction in Scope-1 emissions
- **Societal:** Safer working environment, attracting more skilled workers

Through GLN, Jubilant Ingrevia showcases its commitment to digital transformation, to enhance efficiencies, further environmental sustainability and ensure a positive societal impact



Business Segments Overview

1 Specialty Chemicals | Market, Business & Financial Highlights

MARKET HIGHLIGHTS



Pharma

Steady demand from the end-use segment, volumes remain strong; pricing remained steady with uptick in select segments



Agrochemical

Inventory destocking seems to be approaching its final stages

Witnessed slight uptick in volumes



CDMO

Witnessing rising number of inbound inquiries from the Agro, Pharma, and Semiconductor sectors

FINANCIAL HIGHLIGHTS

Particulars ¹	Q2'FY24	Q1'FY25	Q2'FY25	Q-o-Q	Y-o-Y	H1'FY24	H1'FY25	Y-o-Y
Segment Revenue	382	431	433	1%	13%	745	864	16%
% Share of Overall Revenue	37%	42%	41%			36%	42%	
EBITDA	69	86	87	1%	26%	126	172	37%
% EBITDA Margin	18%	20%	20%			17%	20%	
% Contribution to EBITDA ²	59%	59%	57%			46%	58%	

- Revenue increased on a YoY basis on account of higher volumes coming from Pyridine's building blocks and derivatives
- Healthy volumes uptake and efficiency-led initiatives (**Lean**) improved margins

BUSINESS HIGHLIGHTS

- CDMO business remains on the growth trajectory, signed USD 300 Million+, 5-year CDMO contract with an MNC Agro Innovator
- Witnessed increase in volumes of high-margin Fine Chemicals Pyridine derivatives both QoQ and YoY
- The Di-ketene plant operated at a healthy utilization levels, with good volume traction in the newly commissioned facility
- Pyridine building block volumes remained robust throughout the quarter
- Pyrithiones platform enjoying strong market acceptance, showing QoQ & YoY growth

1. All figures are in Rs Crore unless otherwise stated.
2 Before adjustment of Unallocated corporate expense/income

2 Nutrition & Health Solutions | Market, Business & Financial Highlights

MARKET HIGHLIGHTS



Feed B3

Witnessed improved Niacinamide pricing on QoQ basis
Increased sales volume and gained market share despite stagnant global demand



Food & Cosmetic B3

Witnessed steady demand for food-grade and cosmetic-grade products
On-boarded several new food-grade customers during the quarter



Choline

Volumes remained steady; Pricing under pressure from imports
Improving product mix and executing cost optimisation initiatives to grow margins

FINANCIAL HIGHLIGHTS

Particulars ¹	Q2'FY24	Q1'FY25	Q2'FY25	Q-o-Q	Y-o-Y	H1'FY24	H1'FY25	Y-o-Y
Segment Revenue	162	186	182	-2%	12%	364	368	1%
% Share of Overall Revenue	16%	18%	17%			17%	18%	
EBITDA	19	23	24	5%	29%	36	47	33%
% EBITDA Margin	12%	12%	13%			10%	13%	
% Contribution to EBITDA ²	16%	16%	16%			13%	16%	

- Revenue for the quarter improved YoY on account of higher volumes from sale of both animal and human grade Niacinamide with higher pricing
- Improvement in EBITDA on QoQ and YoY basis due to:
 - Higher prices of Niacinamide
 - Favorable shift in volume mix towards human-grade products
 - Lean initiatives and optimized input cost

BUSINESS HIGHLIGHTS

- Continued focus on improving market share from customers in niche segments i.e. Cosmetics and Food grade resulted in increased volume and revenue from the segment on a QoQ basis
- Newly launched products. i.e 'Food Grade Choline Chloride' and 'Choline Bitartrate' continue getting traction in market
- GMP-compliant facility for Food & Cosmetic grade Niacinamide is expected to be commissioned in Q3'FY25, already started receiving inquiries

1. All figures are in Rs Crore unless otherwise stated.
2 Before adjustment of Unallocated corporate expense/income

3 Chemical Intermediates | Market, Business & Financial Highlights

MARKET HIGHLIGHTS



Volumes

The primary end-use markets for Paracetamol continued to face challenges
Modest recovery was observed in the Agrochemicals end-use sector
Ethyl Acetate Volumes witnessed YoY improvement



Cost

Rising logistics costs, driven by the overall increase in ocean freight resulting from the container crisis, constrained overall margins



Price

Acetic Anhydride prices remained low due to consequent decline in Acetic acid prices

FINANCIAL HIGHLIGHTS

Particulars ¹	Q2'FY24	Q1'FY25	Q2'FY25	Q-o-Q	Y-o-Y	H1'FY24	H1'FY25	Y-o-Y
Segment Revenue	476	408	430	5%	-10%	985	838	-15%
% Share of Overall Revenue	47%	40%	41%			47%	40%	
EBITDA	50	36	40	13%	-20%	110	76	-31%
% EBITDA Margin	11%	9%	9%			11%	9%	
% Contribution to EBITDA ²	25%	25%	27%			41%	26%	

- Ethyl Acetate volumes improved on YoY basis, whereas Acetic Anhydride volumes were benign on account of lower demand from paracetamol end-use
- EBITDA for the quarter improved on a QoQ basis, driven by marginally higher volumes and cost saving initiatives.

BUSINESS HIGHLIGHTS

- Acetic Anhydride market share in Europe remained firm, increased penetration by acquiring new customers
- Retained dominant market share for Acetic Anhydride in domestic market
- On YoY basis, Improved volumes in Ethyl Acetate, strategically serving customers based on economic viability

1. All figures are in Rs Crore unless otherwise stated.
2. Before adjustment of Unallocated corporate expense/Income

Annexures

Annexure I - Income Statement | Consolidated – Q2 & H1'FY25



Particulars ¹	Q2'FY24	Q1'FY25	Q2'FY25	QoQ	YoY	H1'FY24	H1'FY25	YoY
Revenue from operations								
a) Sales/Income from operations	1011	1010	1029	2%	2%	2080	2039	-2%
b) Other operating income	9	14	16	17%	84%	15	30	98%
Total revenue from operations	1020	1024	1045	2%	2%	2095	2070	-1%
Other income	9	10	10	9%	23%	17	20	18%
Total income	1028	1034	1056	2%	3%	2112	2090	-1%
Expenses								
a) Cost of materials consumed	473	532	512	-4%	8%	1052	1044	-1%
b) Purchases of stock-in-trade	8	7	8	11%	3%	21	16	-27%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	18	-11	-13	19%	-169%	-31	-24	-24%
d) Employee benefits expense	103	102	113	11%	9%	197	214	9%
e) Finance costs	12.5	14.3	15.1	6%	20%	24	29	22%
f) Depreciation and amortisation expense	34	39	40	2%	17%	66	78	19%
g) Other expenses:								
- Power and fuel expense	133	118	127	8%	-4%	293	245	-16%
- Others	167	167	174	4%	4%	329	340	3%
Total expenses	949	968	975	1%	3%	1951	1943	0%
Profit before share of loss of an associate (3-4)	80	66	80	22%	1%	161	146	-9%
Share of loss of an associate	0	0	0			0	0	-250%
Profit before tax	80	66	80	21%	0%	161	146	-9%
Tax expense								
- Current tax	13	12	25	104%	102%	29	38	29%
- Deferred tax charge	10	5	-4			17	1	-97%
Net profit for the period/year	57	49	59	21%	3%	115	108	-6%
Earnings per share of ₹ 1 each								
Basic (₹)	3.6	3.1	3.7			7.3	6.8	
Diluted (₹)	3.6	3.1	3.7			7.3	6.8	

1. All figures are in Rs Crore unless otherwise stated.

Expenses covered in Other expenses include i) Consumption of stores and spares and packing materials. ii) Repairs and maintenance, iii) Freight & forwarding (including ocean freight). iv) Others

Annexure II: Income Statement Segmental – Q2 & H1'FY25



Particulars ¹	Q2'FY24	Q1'FY25	Q2'FY25	QoQ (%)	YoY (%)	H1'FY24	H1'FY25	YoY (%)
Total Revenue from Operations	1,020	1,024	1,045	2%	2%	2,095	2,070	(1%)
Speciality Chemicals	382	431	433	1%	13%	745	864	16%
Nutrition & Health Solutions	162	186	182	(2%)	12%	364	368	1%
Chemical Intermediates	476	408	430	5%	(10%)	985	838	(15%)
Reported EBITDA	126	119	135	13%	7%	251	254	1%
Speciality Chemicals	69	86	87	1%	26%	126	172	37%
Nutrition & Health Solutions	19	23	24	5%	29%	36	47	33%
Chemical Intermediates	50	36	40	13%	(20%)	110	76	(31%)
Unallocated Corporate (Expenses)/Income	-12	-25	-16	(36%)	36%	-20	-41	102%
PAT	57	49	59	21%	3%	115	108	(6%)
EPS	3.6	3.1	3.7	21%	2%	7.3	6.8	(6%)
Reported EBITDA Margins	12.4%	11.6%	12.9%			12.0%	12.3%	
Speciality Chemicals	18.1%	19.9%	20.0%			16.9%	19.9%	
Nutrition & Health Solutions	11.5%	12.4%	13.3%			9.8%	12.8%	
Chemical Intermediates	10.6%	8.7%	9.3%			11.2%	9.0%	
Net Margin	5.6%	4.8%	5.6%			5.5%	5.2%	

1. All figures are in Rs Crore unless otherwise stated.

Annexure III: Debt Position | As on 30th September 2024




Particulars ¹	30-Sep-23	30-Jun-24	30-Sep-24
Long Term Borrowings	300	450	450
Short Term Borrowings	457	291	263
Total Gross Debt	757	741	713
Cash & Equivalent	56	64	63
Total Net Debt	701	677	650
YoY change			-7%

- The capex for the quarter was Rs 91 Cr and YTD was Rs 207 Cr, which was primarily funded through internal accruals
- Net Working Capital 'Percentage to Turnover' for Q2 FY'25 was lower at 17.1% as against 24.3% in Q2'FY24
- Reduced Number of days of Working capital to 63, as against 89 in Q2'FY24

Annexure III - Conference Call Details



Date : October 22nd, 2024
Time : 05:00 pm IST

Diamond Pass Log-In	
Pre-registration:	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p> <p> Click here to Express/Join the Call</p> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p>
Conference Dial-In Numbers	
Universal Access:	<p>+ 91 22 6280 1141</p> <p>+ 91 22 7115 8042</p>
Toll Free Number:	<p>USA: 1 866 746 2133</p> <p>UK: 0 808 101 1573</p> <p>Singapore: 800 101 2045</p> <p>Hong Kong: 800 964 448</p>
Audio Link:	<p>The Audio link will be available on the company website. Please access the link here - https://jubilantingrevia.com/investors/financials/quarterly-results</p>

For More Information



Thank you for your time

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has over 2,300 employees and serves over 1,500 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Jubilant Ingrevia Limited is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.

For more information, please visit: www.jubilantingrevia.com

For Investors:

Pavleen Taneja

Jubilant Ingrevia Limited.

- Ph: +91 120 436 1000
- E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar, CDR India

- Ph: +91 22 6645 1209
- E-mail: siddharth@cdr-india.com

For Media:

Sandipan Ghatak

- Ph: +91 120 436 1000
- E-mail: sandipan.ghatak@jubl.com